Esperion Therapeutics Inc.

10/25/2021 | Press release | Distributed by Public on 10/25/2021 05:08

ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock